Seattle biotech Kineta lands $4M contract to develop immunotherapy for infectious disease
The growing market for immunotherapy treatments isn't just focused on cancer.
Seattle biotech Kineta just landed a federal contract from the National Institutes of Health for about $4 million to develop an immunotherapy treatment which would treat a variety of infectious diseases, such as the flu, dengue fever, Ebola and others.
Kineta develops drugs for chronic pain, autoimmune and infectious diseases. The funding will be used to bring a specific drug candidate to the pre-clinical stage, with…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Annie Zak Source Type: news
More News: Autoimmune Disease | Biotechnology | Cancer | Cancer & Oncology | Chronic Pain | Contracts | Dengue Fever | Ebola | Funding | Health | Health Management | Immunotherapy | Infectious Diseases | National Institutes of Health (NIH) | Pain | Pharmaceuticals